When was Vyvgart Hytrulo approved by the FDA?

Written by Joana Carvalho, PhD | July 11, 2023

When was Vyvgart Hytrulo approved by the FDA?

Category: Vyvgart Hytrulo

The U.S. Food and Drug Administration (FDA) approved Vyvgart Hytrulo in June 2023 to treat adults with generalized myasthenia gravis (gMG) who are positive for antibodies targeting the acetylcholine receptor. With that decision, Vyvgart Hytrulo became the first therapy administered via an under-the-skin injection to gain approval in the U.S. for gMG.

Print This Article

About the Author

Joana Carvalho, PhD Joana holds a BSc in Biology, a MSc in Evolutionary and Developmental Biology, and a PhD in Biomedical Sciences from Universidade de Lisboa, Portugal. Her work has been focused on the impact of non-canonical Wnt signaling in the collective behavior of endothelial cells — those that make up the lining of blood vessels — found in the umbilical cord of newborns. In addition to several research fellowships, she was awarded two Erasmus scholarships to conduct part of her studies in France. She has also authored several research papers published in peer-reviewed international scientific journals. Joana joined Bionews in 2018, starting as a science writer, then moving to a science editor position in 2020, and to editorial associate director of resource pages in 2025.